EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Caterina De Barba, Caterina Mucherino, Elvira D'Antonio, Laura Montesano, Manuela Marzo, Franco Scaldaferri, Daniele Napolitano und 45 weitere

Intestinal Research · 30.04.2026 · 24 (2) · 341-351

DOI: 10.5217/ir.2025.00067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, erschienen am 30.04.2026. Verfasst von Antonio Tursi und 56 weiteren Autor:innen. Beteiligte Einrichtung: Territorial Gastroenterology Service, ASL BAT, Andria, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Real-world data on the use of filgotinib (FILGO) in patients with ulcerative colitis (UC) are limited. This study aims to provide consistent results on the effectiveness and safety of FILGO in treating UC.

Methods

A retrospective assessment of clinical and endoscopic activity was conducted in a cohort of patients with UC according to the full Mayo score. The primary co-endpoints of the study were the evaluation of the effectiveness and safety of FILGO.

Results

We enrolled 102 patients with a median follow-up of 24 weeks (interquartile range, 8–24 weeks). At 8 weeks and the end of follow-up, clinical remission was achieved by 38 (37.2%) and 47 (46.1%) patients, respectively. Clinical remission was achieved in 13 of 18 patients (72.2%) receiving first-line therapy, 7 of 19 patients (36.8%) receiving second-line therapy, and 27 of 65 patients (41.5%) receiving third-line therapy (P= 0.002). Clinical remission at 8 weeks predicted clinical remission at the end of follow-up (P= 0.021). Age > 40 years (P= 0.046) and being on second- or third-line of treatment (P= 0.005) were negative predictors for clinical remission. Seventy-one patients (69.6%) achieved a clinical response. At endoscopic evaluation, mucosal healing was observed in 18 out of 30 patients (60.0%). Steroid-free remission was present in 38 out of 46 patients (82.6%). Five patients (4.9%) needed colectomy. Adverse events were recorded in 6 patients (5.8%): 2 cases (2%) were severe, requiring discontinuation of FILGO.

Conclusions

Our real-world data confirms that FILGO is safe and effective for patients with UC. Its efficacy is significantly improved when used as a first-line treatment.

Schlagwörter

Stichwörter der Autor:innen

FilgotinibReal lifeRemissionSafetyUlcerative colitis

Autor:innen und Institutionen

  • Territorial Gastroenterology Service, ASL BAT, Andria, Italy.
  • Department of Medical and Surgical Sciences, Catholic University, School of Medicine, Rome, Italy.
  • Division of Gastroenterology, AORN "Brotzu" Hospital, Cagliari, Italy.
  • IBD Unit, Department of General Surgery and Gastroenterology, Pisa University Hospital, Pisa, Italy.
  • Gastroenterology Unit, Azienda Ospedale-Università di Padova (AOUP), Padua, Italy.
  • Division of Gastroenterology, Azienda Ospedaliera "S. Anna e S. Sebastiano", Caserta, Italy.

Zitieren

APA

Tursi, A., Mocci, G., Costa, F., Ceccarelli, L., Savarino, E., De Barba, C., Mucherino, C., D'Antonio, E., Montesano, L., Marzo, M., Scaldaferri, F., Napolitano, D., Pugliese, D., Gravina, A. G., Pellegrino, R., Spagnuolo, R., Luzza, F., Cuomo, A., Donnarumma, L., …, & Papa, A. (2026). Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study. Intestinal Research, 24(2), 341-351. https://doi.org/10.5217/ir.2025.00067

Vancouver

Tursi A, Mocci G, Costa F, Ceccarelli L, Savarino E, De Barba C, et al. Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study. Intestinal Research. 2026;24(2):341-351. doi:10.5217/ir.2025.00067

BibTeX
@article{Tursi2026,
  author = {Tursi, Antonio and Mocci, Giammarco and Costa, Francesco and Ceccarelli, Linda and Savarino, Edoardo and De Barba, Caterina and Mucherino, Caterina and D'Antonio, Elvira and Montesano, Laura and Marzo, Manuela and Scaldaferri, Franco and Napolitano, Daniele and Pugliese, Daniela and Gravina, Antonietta Gerarda and Pellegrino, Raffaele and Spagnuolo, Rocco and Luzza, Francesco and Cuomo, Antonio and Donnarumma, Laura and Maconi, Giovanni and Cataletti, Giovanni and Bertani, Lorenzo and Bodini, Giorgia and Pasta, Andrea and Piergallini, Simona and Serio, Mariaelena and Scarcelli, Antonella and Capone, Pietro and Cortellini, Fabio and Rodino, Stefano and Sebkova, Ladislava and Vespere, Giuliana and Sedda, Silvia and D'Onofrio, Vittorio and De Luca, Leonardo and Gaiani, Federica and Kayali, Stefano and Pagnini, Cristiano and Graziani, Maria Giovanna and Di Paolo, Maria Carla and Allegretta, Leonardo and Cazzato, Alessia Immacolata and Scorza, Stefano and Ferronato, Antonio and Ribaldone, Davide Giuseppe and Aragona, Giovanni and Perazzo, Patrizia and Forti, Giacomo and Di Fonzo, Michela and Iacopini, Federico and Pica, Roberta and Cassieri, Claudio and Onidi, Francesca Maria and Usai Satta, Paolo and Elisei, Walter and Picchio, Marcello and Papa, Alfredo},
  title = {Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study},
  journal = {Intestinal Research},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {341--351},
  doi = {10.5217/ir.2025.00067}
}
Kostenlos starten →